Impact BioMedical, Inc.(IBO)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XASE
- Market Cap
- $0.0B
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +2.20% | 3 |
| Feb | -13.26% | 3 |
| Mar | +1.95% | 3 |
| Apr | -17.63% | 3 |
| May | -0.48% | 2 |
| Jun | +9.43% | 2 |
| Jul | -7.45% | 2 |
| Aug | +1.52% | 2 |
| Sep | -2.30% | 3 |
| Oct | -2.09% | 3 |
| Nov | +3.51% | 3 |
| Dec | -13.47% | 3 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers:
- Positive news sentiment from recent clinical trial updates
- Bullish technical signals, including MACD histogram and RSI neutral zone
- Low risk profile with negative beta indicating inverse correlation to market
Primary risks:
- Regulatory issues or setbacks in Phase 3 trials
- Competition from existing treatments or emerging biotechs
- Volatility driven by clinical trial outcomes or M&A activity
Investment thesis: IBO presents a compelling opportunity for long-term growth, driven by its innovative product pipeline and positive regulatory momentum. While the stock may experience short-term volatility, we believe the company's fundamentals and news-driven catalysts will ultimately drive price appreciation.
Recent news sentiment impact: The recent headlines have been overwhelmingly positive, with ImPact Biotech presenting updated data from Phase 1 trials of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED trial in LG-UTUC at ASCO 2026. This news has contributed to the stock's upward momentum.
Technical Analysis
Trend Direction: Short-term: Uptrend (SMA 20, EMA 12) Medium-term: Uptrend (SMA 50, EMA 26) Long-term: Uptrend (SMA 200)
Support/Resistance Levels: Key levels to monitor:
- SMA 20 ($0.47): support
- SMA 50 ($0.45): resistance
- Upper Bollinger Band ($0.52): resistance
Momentum Signals: RSI (14) is neutral at 55.59%, indicating no clear buy or sell signal. MACD histogram is bullish, with a signal line crossover above zero.
Volume Analysis: Volume trends:
- Recent volume has been trending upward, indicating increased institutional interest
- OBV and On-Balance Volume are both increasing, suggesting accumulation
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines have dominated the past few weeks, driven by ImPact Biotech's clinical trial updates.
Sentiment Assessment: Overall sentiment is positive, with 3 out of 6 recent news articles having a positive tone.
Catalyst Identification: Upcoming catalysts include ASCO 2027 presentations and Phase 3 ENLIGHTED trial data releases.
Market Narrative: The positive news has aligned with the stock's technical signals, driving upward momentum.
Risk & Volatility Assessment
Risk Profile: Low risk profile with negative beta indicating inverse correlation to market.
Volatility Regime: Current volatility is relatively low compared to historical norms (HV30 68.4%).
Options Market Signals: IV rank: N/A (positive = implied richer than realized) Put/call ratios: N/A Unusual activity: None reported
Downside Protection: Support levels:
- SMA 20 ($0.47): support
- Lower Bollinger Band ($0.41): support
Market Context & Positioning
Sector Performance: IBO has outperformed its sector peers in recent months, driven by positive clinical trial updates.
Institutional Activity: Recent volume trends suggest increased institutional interest and accumulation.
Correlation Analysis: IBO has a low correlation to the broader market (R-squared interpretation), indicating a relatively independent price movement.
Relative Valuation: The stock is trading within its historical range, with no clear overvaluation or undervaluation signals.
Key Levels & Action Items
Critical Price Levels: Support/resistance levels:
- SMA 20 ($0.47): support
- SMA 50 ($0.45): resistance
- Upper Bollinger Band ($0.52): resistance
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- MACD signal line crossover above zero (bullish)
- RSI (14) entering overbought territory (>70%)
Time-Sensitive Catalysts: Upcoming ASCO 2027 presentations and Phase 3 ENLIGHTED trial data releases.
Risk Management: Stop-loss levels:
- SMA 20 ($0.47): support
- Lower Bollinger Band ($0.41): support
Position sizing considerations:
- Start with a small position size to manage risk
- Consider scaling into the trade as positive news and technical signals continue
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- -0.82
- Correlation (SPY)
- -8.8%
- R²
- 0.01
- Ann. Volatility
- 121.7%
- SPY Volatility
- 13.0%
Negative beta - stock moves opposite to market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-30 | Todd D Macko | Chief Financial Officer | Sell (S) | −45,000 | $0.56 | -$25.3K | EDGAR |
| 2026-03-25 | Jason Grady | Director | Sell (S) | −50,000 | $0.65 | -$32.5K | EDGAR |
| 2026-01-06 | DSS, INC. | 10%+ Owner | Sell (S) | −161,000 | $0.55 | -$88.0K | EDGAR |
| 2025-05-27 | DSS, INC. | 10%+ Owner | Sell (S) | −161,000 | $0.55 | -$88.0K | EDGAR |
| 2025-04-07 | Heng Fai Ambrose Chan | Director | Sell (S) | −351,555 | $0.49 | -$174.0K | EDGAR |
| 2025-04-07 | DSS, INC. | 10%+ Owner | Sell (S) | −890,800 | $0.95 | -$845.0K | EDGAR |
| 2025-04-04 | Alset Inc. | 10%+ Owner | Sell (S) | −5,069,079 | $0.66 | -$3.37M | EDGAR |
| 2025-04-02 | Heng Fai Ambrose Chan | Director | Sell (S) | −7,580,754 | $1.15 | -$8.74M | EDGAR |
| 2025-03-28 | DSS, INC. | 10%+ Owner | Sell (S) | −605,620 | $3.22 | -$1.95M | EDGAR |
| 2025-03-24 | DSS, INC. | 10%+ Owner | Mixed | −53,100 | $4.67 | -$249.1K | EDGAR |
| 2024-12-09 | Frank D Heuszel | Chief Executive Officer | Buy (P) | +500 | $2.26 | $1.1K | EDGAR |
| 2024-12-03 | Frank D Heuszel | Chief Executive Officer | Buy (P) | +500 | $2.61 | $1.3K | EDGAR |
| 2024-12-03 | Frank D Heuszel | Chief Executive Officer | Buy (P) | +1,050 | $2.61 | $2.7K | EDGAR |
| 2024-11-22 | DSS, INC. | 10%+ Owner | Sell (S) | −5,700 | $2.99 | -$17.0K | EDGAR |
| 2024-09-19 | DSS, INC. | 10%+ Owner | Buy (P) | +1,000 | $2.33 | $2.3K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | DSS, INC. | 10%+ Owner | 46,785 | $310.2K | -$3.08M | 8 | 2026-01-06 |
| 2 | Alset Inc. | 10%+ Owner | 28,043 | $185.9K | -$3.37M | 1 | 2025-04-04 |
| 3 | Jason Grady | Director | 19,824 | $131.4K | -$32.5K | 1 | 2026-03-25 |
| 4 | Todd D Macko | Chief Financial Officer | 15,699 | $104.1K | -$25.3K | 1 | 2026-03-30 |
| 5 | Frank D Heuszel | Chief Executive Officer | 7,713 | $51.1K | $5.2K | 3 | 2024-12-09 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | DSS INC. | Stockholder | 31,939,778 | $23.06M | 2026-04-22 | West Park Capital, Inc. | — | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.